However, management and treatment decisions of VEGF inhibitors-induced cardiac ischemia should be individualized according to cancer severity, life expectancy, comorbidities, or alternative highly efficient chemotherapeutic agents [4,14,32]. This evidence concerns the gene VEGFA and myocardial ischemia.